Screener
Ironwood Pharmaceuticals IRWD Royalty — Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Ironwood Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Ironwood Pharmaceuticals’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:07 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-091987
The Company recognized $1.1 million and $1.9 million of royalty revenue during the three and six months ended June 30, 2026, respectively. The Company recognized $0.9 million and $1.7 million of royalty revenue during the three and six months ended June 30, 2025, respectively.
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is Ironwood Pharmaceuticals's royalty — revenue?
- Ironwood Pharmaceuticals (IRWD) reported royalty — revenue of $1.1M in Q2 2026.
- How has Ironwood Pharmaceuticals's royalty — revenue changed year-over-year?
- Ironwood Pharmaceuticals's royalty — revenue increased by 22.2% year-over-year, from $900K to $1.1M.
- What does royalty — revenue mean?
- This metric represents the gross revenue recognized from royalty-based arrangements associated with specific pharmaceutical products or intellectual property licenses, excluding any assessed taxes. It reflects the income generated through contractual rights to receive a percentage of sales or other performance-based payments from partners or licensees. Monitoring this figure helps investors assess the recurring cash flow stability and the long-term commercial performance of the company's licensed therapeutic portfolio.
Ask your AI about Ironwood Pharmaceuticals's royalty — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude